Shen Lian Biomedical shareholders end concerted action, equity structure shifts

Shanghai Shen Lian Biomedical Corporation announced the termination of a concerted action relationship among its controlling shareholders, effective December 19, 2025. This change stemmed from the alteration of the executive partner of Shanghai Shentai Lian Investment Partnership (Limited Partnership) from Yipu Business Consulting Co., Ltd. to Mr. Wang Rui. This resulted in the cessation of the concerted action agreement between Shentai Lian and controlling shareholders Nie Dong sheng, Yang Yufang, Yang Congzhou, and Wang Dongliang. While individual shareholdings remain unchanged, their combined voting power, previously 35.82%, is now calculated at 30.78% due to the uncoupling of Shentai Lian's 5.04% stake.

Despite this adjustment, the company's controlling shareholders and actual controllers remain Nie Dong sheng, Yang Yufang, Yang Congzhou, and Wang Dongliang. The termination of the concerted action relationship does not affect their status or the company's operational stability, and there are no plans for further share increases or decreases within the next 12 months from the involved parties.

In a separate development, the company's associate, Yangzhou Shizhiyuan Biotechnology Co., Ltd., recently obtained a patent for "Treatment and Functional Cure of HIV Infection by CD4-Mediated Monoclonal Antibody Competitive Inhibition of HIV Entry," dated December 5, 2025. This patent covers a novel mechanism for HIV treatment using UB-421, enhancing the company's intellectual property in innovative drug development.